Ayala Pharmaceuticals (NASDAQ:AYLA) and Windtree Therapeutics (OTCMKTS:WINT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.
Institutional & Insider Ownership
20.3% of Ayala Pharmaceuticals shares are owned by institutional investors. 14.9% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This is a summary of current ratings for Ayala Pharmaceuticals and Windtree Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ayala Pharmaceuticals currently has a consensus price target of $24.00, indicating a potential upside of 91.08%. Windtree Therapeutics has a consensus price target of $12.25, indicating a potential upside of 80.41%. Given Ayala Pharmaceuticals’ higher probable upside, research analysts plainly believe Ayala Pharmaceuticals is more favorable than Windtree Therapeutics.
This table compares Ayala Pharmaceuticals and Windtree Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Ayala Pharmaceuticals and Windtree Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Windtree Therapeutics||$200,000.00||573.28||-$27.48 million||N/A||N/A|
Ayala Pharmaceuticals has higher earnings, but lower revenue than Windtree Therapeutics.
Ayala Pharmaceuticals beats Windtree Therapeutics on 5 of the 8 factors compared between the two stocks.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.
Windtree Therapeutics Company Profile
Windtree Therapeutics, Inc., a biotechnology company, focuses on developing surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform includes a synthetic peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and drug-delivery technologies being developed to enable the noninvasive administration of aerosolized KL4 surfactant. The company's lead development program comprises AEROSURF, a drug/device product that has completed Phase IIb clinical trial to treat respiratory distress syndrome in premature infants. It is also developing other aerosolized KL4 surfactant products. Windtree Therapeutics, Inc. has a strategic collaboration with Eleison Pharmaceuticals, Inc. for using its proprietary aerosol delivery system to deliver inhaled lipid cisplatin in combination with KL4 surfactant. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.